Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05059522 · ClinicalTrials.gov registry record · Phase 3
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
A Phase 3 study of Ovarian Cancer and Solid Tumors, sponsored by Pfizer.
- Active
- Registry status
- Phase 3
- Development phase
- 68
- Enrollment target
- 20
- Study locations
NCT05059522: Active Phase 3 study of Ovarian Cancer and Solid Tumors, sponsored by Pfizer.
NCT05059522 is a Phase 3 study of Ovarian Cancer and Solid Tumors that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 68 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05059522, a Phase 3 study of Ovarian Cancer and Solid Tumors, is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 68 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.
Conditions Studied
Interventions
- DRUG Pemetrexed
- DRUG Talazoparib
- DRUG Axitinib
- DRUG Avelumab
- DRUG Lorlatanib
Study Locations (20)
New York
- MSK Commack - Commack
- MSK Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street). - New York
- Memorial Sloan Kettering Cancer Center 53rd street. - New York
- Memorial Sloan Kettering Cancer Center - New York
- MSK Nassau - Uniondale
Arkansas
- Highlands Oncology Group, PA - Fayetteville
- Highlands Oncology Group, PA - Rogers
- Highlands Oncology Group, PA - Springdale
New Jersey
- MSK Basking Ridge - Basking Ridge
- MSK Monmouth - Middletown
- MSK Bergen - Montvale
New South Wales
- Macquarie University - North Ryde
- Mater Hospital Sydney - Wollstonecraft
- Melanoma Institute Australia - Wollstonecraft
California
- UCLA Hematology/Oncology - Los Angeles
Florida
- Moffitt Cancer Center - Tampa
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2021-09-29 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 3 |
What the registry record for NCT05059522 still lists
NCT05059522 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (91% lower).
The record links to 5 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pemetrexed is the first listed.
NCT05059522 names 20 study sites across 9 states, led by New York, Arkansas, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05059522 about?
NCT05059522 is a clinical study titled "Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing". This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.
What is the current status of trial NCT05059522?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 68 participants. The study started on 2021-09-29. Estimated completion is 2026-09-30.
What conditions does trial NCT05059522 study?
This clinical trial studies the following conditions: Ovarian Cancer, Solid Tumors, NSCLC, Urothelial Cancer, Advanced Malignancies.
What interventions are being tested in trial NCT05059522?
The interventions under investigation include: Pemetrexed (DRUG), Talazoparib (DRUG), Axitinib (DRUG), Avelumab (DRUG), Lorlatanib (DRUG).
Who is sponsoring clinical trial NCT05059522?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05059522 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05059522's enrollment target sits among peer trials
68 184th of 322 higher than 139 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RECRUITING · Phase 3
-
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
RECRUITING · Phase 3
-
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
RECRUITING · Phase 3
-
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI